Have we forgotten the purpose of phase III studies?
Flynn
Joseph M
JM
Byrd
John C
JC
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000187:drug effects; D000951:Antigens, Neoplasm / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000074301:CD52 Antigen; D002699:Chlorambucil / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic / Q000379:methods; D017322:Clinical Trials, Phase II as Topic / Q000379:methods; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D006023:Glycoproteins / Q000187:drug effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D002699:Chlorambucil; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine